Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a beam of light boost acne treatment?

NCT ID NCT07777952

Disease control Sponsor: Mahmoud Rageh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether adding a targeted ultraviolet light treatment to a common antibiotic can better reduce inflammatory acne. People aged 15 to 35 with acne on both sides of the face will take oral azithromycin, and one randomly chosen side of the face will also receive excimer light twice a week for 8 weeks. The other side serves as a comparison. Researchers will count pimples and assess skin improvement to see if the light adds benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
308-nm excimer light (a type of ultraviolet light) added to oral azithromycin (an antibiotic)
What this could lead to
If effective, adding excimer light to antibiotic therapy could offer a new way to speed up acne clearing and reduce reliance on antibiotics alone.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. The light can cause redness or irritation, and the benefit over antibiotics alone is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

32 people

The number who actually took part.

Started

Oct 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants. * age 15-35 years. * Bilateral inflammatory acne involving both hemifaces, with clinically comparable baseline inflammatory involvement as assessed before randomization. * No topical or systemic acne treatment during the preceding 8 weeks. Exclusion Criteria: * Pregnancy. * Photosensitivity disorders. * Macrolide hypersensitivity. * Concurrent isotretinoin use or isotretinoin use during the preceding 8 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne vulgaris are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne vulgaris

Contacts and locations

Locations

  • Al-Azhar University Hospital

    Damietta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.